The phase 1 data from Allogene's ALPHA and ALPHA2 trials in relapsed/refractory large B-cell lymphoma is published, representing a milestone demonstrating the utility of allogeneic CAR-T therapies ...

Then, dear Seeking Alpha readers, you may have the first question, namely, what factors contributed to the beat of Wall Street analysts and my expectations? So, Pfizer's revenue growth was driven ...